A revolution in Neuro Precision Diagnostics

A 1st time right diagnosis

CLARIK offers automated, timely and objective diagnosis of neurodegenerative diseases such as Alzheimer’s and Parkinson’s, through reliable, affordable, and accessible AI-based neuroimaging biomarkers.

Our Solutions

  • Clinical decision support systems (CDSS’s) providing a report with differential diagnosis and staging of the disease

  • Precision tool for pharmaceutical companies, allowing accurate patients’ stratification, eligibility and disease progression on clinical studies

  • Research precision diagnostics platform for new digital biomarkers

Learn more about our Solutions

Our approach

A pre-condition to reach personalized medicine is precision diagnostics. Hand in hand with the need for more effective treatments and cure, reaching an earlier and accurate diagnosis is critical. Today, there is no single clinical test for the conclusive diagnosis of most neurodegenerative diseases, such as Alzheimer’s or Parkinson’s Disease.

Reduce Diagnosis Time

Our approach allows a timely and first time right diagnosis avoiding multiple tests until disease confirmation.

Increase Diagnosis Accessibility

Our approach uses easily accessible neuroimaging equipment, widely available in most clinical settings around the world, while reducing the need for multiple tests.

Promote Healthcare Sustainability

A timely and accurate first diagnosis allows for a quick and timely intervention, supported by precise diagnosis of staging and typologies to enable precision interventions with better results for patient health and healthcare systems. 

Our Solutions Pipeline

a single diagnostic test, a 1st time right diagnosis, that is specific and sensitive, widely available (capitalizing on mainstream hospital equipment, MRI), allowing an earlier and accurate diagnosis and staging of these illnesses and response to therapy.

2

Biomarkers in Clinical Stage

CLARIK is currently in clinical stages to secure certification as a Class II Medical Device for biomarkers targeting Alzheimer’s and Parkinson’s Disease.

4+

Biomarkers in Research

CLARIK has currently under research with its clinical partners new biomarkers targeting Frontal Temporal Dementia, Epilepsy, Traumatic Brain Injuring, among others.

PUBLICATIONS

Our scientific team contribute to the growth of the research community. Here a list of some of the the scientific publications they were involved in.

Ribeiro et al. (2015), Multimodal Imaging Brain Connectivity Analysis (MIBCA) toolbox. PeerJ 3:e1078; DOI 10.7717/peerj.1078

RIBEIRO et al.: MULTIMODAL IMAGING OF BRAIN CONNECTIVITY USING THE MIBCA TOOLBOX, IEEE TRANSACTIONS ON NUCLEAR SCIENCE, VOL. 62, NO. 3, JUNE 2015

Latest News

Check our blog